DUBLIN, April 1, 2021 /PRNewswire/ -- The "Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Therapy Type; Product; Technology; Application; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.
According to this report the global cell therapy market is expected to reach US$ 12,563.23 million by 2027 from US$ 7,260.50 million in 2019. It is estimated to grow at a CAGR of 7.2% from 2020-2027. The growth of the market is attributed to increasing prevalence of chronic diseases, rising adoption of regenerative medicines, and surging number of approvals for cell-based therapies. However, the high cost of cell therapy manufacturing hinders the growth of the market.
The cell therapy market, based on therapy type, is bifurcated into allogeneic and autologous. In 2019, the allogeneic segment accounted for a larger share owing to the availability of substantial number of approved products for clinical use. For instance, in 2018, Alofisel developed by TiGenix (Takeda) is the first allogeneic stem cell-based therapy approved for use in Europe.
Chronic diseases, such as cardiovascular disorders, neurological disorders, autoimmune disorders, and cancer, are the leading causes of death and disability worldwide. As per the Centers for Disease Control and Prevention (CDC), in 2019, nearly 6 in 10 people suffered from at least one chronic disease in the US. Cardiovascular diseases (CVDs) are a significant cause of mortality owing to the hectic lifestyle. As per the World Health Organization (WHO), CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Cancer is among the leading causes of mortality worldwide, and the disease affects a huge population; therefore, it acts as a huge financial burden on society. According to the WHO, in 2018, ~9.6 million deaths occurred due to cancer globally. However, growing research on developing effective treatments for the disease is positively affecting the market growth. Gene therapy and cell therapy are transforming the cancer treatment landscape; for example, Novartis Kymriah is used to treat diffuse large B-cell lymphoma. The launches of more such products would be driving the demand for cell therapy, thus driving the growth of the cell therapy market in the coming years.
The COVID-19 outbreak was first reported in Wuhan (China) in December 2019. The pandemic is causing massive disruptions in supply chains, consumer markets, and economy across the world. As the healthcare sector is focusing on saving lives of COVID-19 patients, the demand for cell therapy is reducing worldwide.
Vericel Corporation; MEDIPOST; NuVasive, Inc.; Mesoblast Limited; JCR Pharmaceuticals Co. Ltd.; Smith & Nephew; Bristol-Myers Squibb Company; Cells for Cells; Stemedica Cell Technologies, Inc; and Castle Creek Biosciences, Inc. are among the companies operating in the cell therapy market.
Reasons to Buy
Key Topics Covered:
1. Introduction1.1 Scope of the Study1.2 Research Report Guidance1.3 Market Segmentation1.3.1 Global Cell Therapy Market - By Therapy Type1.3.2 Global Cell Therapy Market - By Product1.3.3 Global Cell Therapy Market - By Technology1.3.4 Global Cell Therapy Market - By Application1.3.5 Global Cell Therapy Market - By End User1.3.6 Global Cell Therapy Market - By Geography
2. Cell Therapy Market - Key Takeaways
3. Research Methodology3.1 Coverage3.2 Secondary Research3.3 Primary Research
4. Global Cell therapy- Market Landscape4.1 Overview4.2 PEST Analysis4.2.1 North America - PEST Analysis4.2.2 Europe- PEST Analysis4.2.3 Asia Pacific- PEST Analysis4.2.4 Middle East and Africa - PEST Analysis4.2.5 South and Central America - PEST Analysis4.3 Expert Opinions
5. Global Cell Therapy Market - Key Industry Dynamics5.1 Key Market Drivers5.1.1 Increasing Prevalence of Chronic Diseases5.1.2 Rising Adoption of Regenerative Medicines5.1.3 Increasing Number of Approvals for Cell-Based Therapies5.2 Key Market Restraints5.2.1 High Cost of Cell Therapy Manufacturing5.3 Key Market Opportunities5.3.1 Increasing Adoption of Cell Therapy in Developing Regions5.4 Future Trends5.4.1 Shift Toward Automated Cell Therapy Manufacturing5.5 Impact Analysis of Drivers and Restraints
6. Cell therapy Market - Global Analysis6.1 Global Cell therapy Market Revenue Forecast And Analysis6.2 Global Cell therapy Market, By Geography - Forecast And Analysis6.3 Market Positioning
7. Cell therapy Market Analysis - By Therapy Type7.1 Overview7.2 Cell therapy Market Revenue Share, by Therapy Type (2019 and 2027)7.3 Allogeneic7.3.1 Overview7.3.2 Allogeneic: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)7.4 Autologous7.4.1 Overview7.4.2 Autologous: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)
8. Cell therapy Market Analysis - By Product8.1 Overview8.2 Cell therapy Market Revenue Share, by Product (2019 and 2027)8.3 Consumables8.3.1 Overview8.3.2 Consumables: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)8.4 Equipment8.4.1 Overview8.4.2 Equipment: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)8.5 Systems and Software8.5.1 Overview8.5.2 Systems and Software: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)
9. Cell therapy Market Analysis - By Technology9.1 Overview9.2 Cell therapy Market Revenue Share, by Technology (2019 and 2027)9.3 Viral Vector Technology9.3.1 Overview9.3.2 Viral Vector Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)9.4 Genome Editing Technology9.4.1 Overview9.4.2 Genome Editing Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)9.5 Somatic Cell Technology9.5.1 Overview9.5.2 Somatic Cell Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)9.6 Cell Immortalization Technology9.6.1 Overview9.6.2 Cell Immortalization Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)9.7 Cell Plasticity Technology9.7.1 Overview9.7.2 Cell Plasticity Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)9.8 Three-Dimensional Technology9.8.1 Overview9.8.2 Three-Dimensional Technology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)
10. Cell therapy Market Analysis - By Application10.1 Overview10.2 Cell therapy Market Revenue Share, by Application (2019 and 2027)10.3 Oncology10.3.1 Overview10.3.2 Oncology: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)10.4 Cardiovascular10.4.1 Overview10.4.2 Cardiovascular: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)10.5 Orthopedic10.5.1 Overview10.5.2 Orthopedic: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)10.6 Wound Management10.6.1 Overview10.6.2 Wound Management: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)10.7 Other Applications10.7.1 Overview10.7.2 Other Applications: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)
11. Cell therapy Market Analysis - By End User11.1 Overview11.2 Cell therapy Market Share, by End User, 2019 and 2027, (%)11.3 Hospitals11.3.1 Overview11.3.2 Hospitals: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)11.4 Research Institutes11.4.1 Overview11.4.2 Research Institutes: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)11.5 Others11.5.1 Overview11.5.2 Others: Cell therapy Market - Revenue and Forecast to 2027 (US$ Million)
12. Cell therapy Market - Geographic Analysis12.1 North America: Cell Therapy Market12.2 Europe: Cell therapy Market12.3 Asia Pacific: Cell Therapy Market12.4 Middle East and Africa: Cell Therapy Market12.5 South and Central America: Cell Therapy Market
13. Impact of COVID-19 Pandemic on Global Cell Therapy Market13.1 North America: Impact Assessment of COVID-19 Pandemic13.2 Europe: Impact Assessment of COVID-19 Pandemic13.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic13.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic13.5 South & Central America: Impact Assessment of COVID-19 Pandemic
14. Cell Therapy Market- Industry Landscape14.1 Overview14.2 Growth Strategies Done by the Companies in the Market, (%)14.3 Organic Developments14.3.1 Overview14.4 Inorganic Developments14.4.1 Overview
15. Company Profiles15.1 Vericel Corporation15.1.1 Key Facts15.1.2 Business Description15.1.3 Products and Services15.1.4 Financial Overview15.1.5 SWOT Analysis15.1.6 Key Developments15.2 MEDIPOST15.2.1 Key Facts15.2.2 Business Description15.2.3 Products and Services15.2.4 Financial Overview15.2.5 SWOT Analysis15.2.6 Key Developments15.3 NuVasive, Inc.15.3.1 Key Facts15.3.2 Business Description15.3.3 Products and Services15.3.4 Financial Overview15.3.5 SWOT Analysis15.3.6 Key Developments15.4 Mesoblast Limited15.4.1 Key Facts15.4.2 Business Description15.4.3 Products and Services15.4.4 Financial Overview15.4.5 SWOT Analysis15.4.6 Key Developments15.5 JCR Pharmaceuticals Co. Ltd.15.5.1 Key Facts15.5.2 Business Description15.5.3 Products and Services15.5.4 Financial Overview15.5.5 SWOT Analysis15.5.6 Key Developments15.6 Smith & Nephew15.6.1 Key Facts15.6.2 Business Description15.6.3 Products and Services15.6.4 Financial Overview15.6.5 SWOT Analysis15.6.6 Key Developments15.7 Bristol-Myers Squibb Company15.7.1 Key Facts15.7.2 Business Description15.7.3 Products and Services15.7.4 Financial Overview15.7.5 SWOT Analysis15.7.6 Key Developments15.8 Cells for Cells15.8.1 Key Facts15.8.2 Business Description15.8.3 Products and Services15.8.4 Financial Overview15.8.5 SWOT Analysis15.8.6 Key Developments15.9 Stemedica Cell Technologies, Inc15.9.1 Key Facts15.9.2 Business Description15.9.3 Products and Services15.9.4 Financial Overview15.9.5 SWOT Analysis15.9.6 Key Developments15.10 Castle Creek Biosciences, Inc.15.10.1 Key Facts15.10.2 Business Description15.10.3 Products and Services15.10.4 Financial Overview15.10.5 SWOT Analysis15.10.6 Key Developments
16. Appendix16.1 About the Publisher16.2 Glossary of Terms
For more information about this report visit https://www.researchandmarkets.com/r/hxk6k0
Media Contact:
Research and Markets Laura Wood, Senior Manager [emailprotected]
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
http://www.researchandmarkets.com
See the rest here:
Worldwide Cell Therapy Industry to 2027 - Increasing Prevalence of Chronic Diseases is Driving the Market - PRNewswire
- 001 Stem cells for a Webby! [Last Updated On: April 28th, 2010] [Originally Added On: April 28th, 2010]
- 002 Stem cells for a Webby! [Last Updated On: April 28th, 2010] [Originally Added On: April 28th, 2010]
- 003 Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- 004 Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- 005 Google to Invest in Regenerative Medicine [Last Updated On: May 5th, 2010] [Originally Added On: May 5th, 2010]
- 006 Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 [Last Updated On: May 22nd, 2010] [Originally Added On: May 22nd, 2010]
- 007 The changing face of PR and why it matters to regenmed [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 008 The changing face of PR and why it matters to regenmed [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 009 Stem Cell Therapy: Age of Human Cell Engineering is Born [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- 010 Using Stem Cells Scientists Grow a Rat Lung, Humans are Next [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 011 FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 012 FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 013 Careers in cell therapy & regenerative medicine [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 014 Careers in cell therapy & regenerative medicine [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 015 The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: January 18th, 2011] [Originally Added On: January 18th, 2011]
- 016 Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: February 7th, 2011] [Originally Added On: February 7th, 2011]
- 017 The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 018 Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 019 In vivo cell trafficking just took a leap forward [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 020 In vivo cell trafficking just took a leap forward [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 021 Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: July 10th, 2011] [Originally Added On: July 10th, 2011]
- 022 Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: July 10th, 2011] [Originally Added On: July 10th, 2011]
- 023 Clinical trial costs [Last Updated On: July 31st, 2011] [Originally Added On: July 31st, 2011]
- 024 Clinical trial costs [Last Updated On: July 31st, 2011] [Originally Added On: July 31st, 2011]
- 025 Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- 026 Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- 027 Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 028 Commercial-stage Cell Therapy Companies and Products [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 029 Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 030 Commercial-stage Cell Therapy Companies and Products [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 031 Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 032 Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 033 Dr Farshchian: Regenerative Medicine shows Potentials - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- 034 Mayo Clinic Regenerative Medicine Consult Service - Video [Last Updated On: October 16th, 2011] [Originally Added On: October 16th, 2011]
- 035 Regenerative Medicine and Applications of Stem Cell Research - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 036 The Future of Stem Cells and Regenerative Medicine - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 037 "You and Your Health" TV Show - Orthopedic Regenerative Medicine - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 038 Closing Remarks, Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 039 Hearing Loss Research: CBR Exclusive! Stem Cells Explored as Cure for Hearing Loss - Video [Last Updated On: October 19th, 2011] [Originally Added On: October 19th, 2011]
- 040 An amazing story of stem cells, regenerative medicine and healing power: - Video [Last Updated On: October 19th, 2011] [Originally Added On: October 19th, 2011]
- 041 What is Regenerative Medicine? | Los Angeles | Hollywood | Beverly Hills - Video [Last Updated On: October 19th, 2011] [Originally Added On: October 19th, 2011]
- 042 A New Era in Regenerative Medicine - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- 043 McEwen Centre for Regenerative Medicine - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- 044 Retroviruses, Reproduction, and Regenerative Medicine: The Influence of Federal Funding - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 045 You and Your Heath TV Show - Orthopedic Regenerative Medicine Part 1 - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 046 TEDxPhoenix - Jane Maienschein - Stem Cells, Regenerative Medicine and Us - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 047 Regenerative Medicine: Pathways to Cure - Version 2.0 - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 048 Opening Remarks, Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine - Video [Last Updated On: October 23rd, 2011] [Originally Added On: October 23rd, 2011]
- 049 Commercializing Cell-based Regenerative Medicines [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- 050 Commercializing Cell-based Regenerative Medicines [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- 051 Coast To Coast AM - 15.11.2011 - 4/4 - Regenerative Medicine/Dulce Base - Video [Last Updated On: November 17th, 2011] [Originally Added On: November 17th, 2011]
- 052 Coast To Coast AM - 15.11.2011 - 1/4 - Regenerative Medicine/Dulce Base - Video [Last Updated On: November 17th, 2011] [Originally Added On: November 17th, 2011]
- 053 Stem Cell Based Therapies for Blindness: David Hinton - CIRM Science Writer's Seminar - Video [Last Updated On: November 18th, 2011] [Originally Added On: November 18th, 2011]
- 054 Dr. Craig Saunders Discusses Stem Cells and Regenerative Medicine at the Evolution of Fat Workshop - Video [Last Updated On: November 24th, 2011] [Originally Added On: November 24th, 2011]
- 055 Coast To Coast AM: Regenerative Medicine / Dulce Base 11-15-2011 Download Link - Video [Last Updated On: November 24th, 2011] [Originally Added On: November 24th, 2011]
- 056 Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- 057 Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- 058 StemCellTV Talks to Elona Baum of the California Institute of Regenerative Medicine - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- 059 StemCellTV Talks to Michael Werner of Alliance for Regenerative Medicine at Meeting on the Mesa - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- 060 StemCellTV Talks to Morrie Ruffin of Alliance for Regenerative Medicine at Meeting on the Mesa - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- 061 Active phase III or II/III cell therapy trials [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 062 Active phase III or II/III cell therapy trials [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 063 2011 Summit: Harnessing Regenerative Medicine for US Service-members, Major General James K. Gilman - Video [Last Updated On: December 17th, 2011] [Originally Added On: December 17th, 2011]
- 064 Recently approved cell therapy products [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 065 Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 066 Recently approved cell therapy products [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 067 Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 068 Coast To Coast AM: 15.11.2011 - Regenerative Medicine/ Dulce Base - Video [Last Updated On: December 22nd, 2011] [Originally Added On: December 22nd, 2011]
- 069 Stem Cell Clinical Trial for Heart Failure: Eduardo Marban - CIRM Spotlight on Disease - Video [Last Updated On: December 23rd, 2011] [Originally Added On: December 23rd, 2011]
- 070 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- 071 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- 072 Regenerative medicine company encouraged by heart failure trial [Last Updated On: January 28th, 2012] [Originally Added On: January 28th, 2012]
- 073 IndiaMART Leaders of Tomorrow AWards 2011 - Regenerative Medical Services Pvt Ltd - Video [Last Updated On: February 8th, 2012] [Originally Added On: February 8th, 2012]
- 074 American CryoStem Joins Alliance for Regenerative Medicine [Last Updated On: February 13th, 2012] [Originally Added On: February 13th, 2012]
- 075 ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from ... [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 076 Biomask: Improving Facial Burn Treatment for Soldiers in the Field [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- 077 Cytomedix to Showcase Aldagen's Promising Autologous Cell Therapy Technology at Two Regenerative Medicine Meetings [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- 078 Histogenics to Present at 7th Annual New York Stem Cell Summit [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- 079 BioTime CEO Michael D. West to Present at New York Stem Cell Summit [Last Updated On: February 18th, 2012] [Originally Added On: February 18th, 2012]
- 080 Makucell(TM) Announces Key Scientific Presentations and Launch of a Large, Multicenter Use Study of Asymmtate(TM) [Last Updated On: February 22nd, 2012] [Originally Added On: February 22nd, 2012]